Patent · US Active

Antiviral agents for drug-resistant influenza A

US11365174B2 · kind B2 · utility

0Cited by

5References

7Claims

0Family size

Assignees

Thomas Jefferson University · US
Ramot at Tel-Aviv University Ltd. · IL

Inventors

Nir Ben-Tal · Nes Ziona, IL
Roger S. Armen · Philadelphia, US
Laurence C. Eisenlohr · Yeadon, US
Jitendra D. Belani · Newton, US
Michael Louis Miller · Framingham, US
Inbar Fish · Sunnyvale, US
Ori Kalid · Rehovot, IL

Key dates

Filing date	Apr 27, 2020
Grant date	Jun 21, 2022
Priority date	—
Expiry date	Apr 27, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07C311/29
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

An effective therapeutic agent for the M2 channel comprising sulfonylamide or oxabicyclo structures effective for treating amantadine-resistant influenza A infections, and methods of treating amantadine-resistant influenza A infections through administration of the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.